Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/271 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME11338782
PMID: | 11338782
LR: | 20061115
CED: | 20010507
DCO: | 20010521
Autoren: | Reginster JY; Henrotin Y
Titel: | Pharma clinics. Comment je traite.... L'arthrose. 2ème partie: nouvelles perspectives thérapeutiques. Pharmacy clinics. How I treat...Osteoarthritis. 2nd part: new therapeutic perspectives
Quelle: | Revue médicale de Liège; VOL: 56 (3); p. 135-9 /200103/
PM: | Print
SU: | IM
Sprache: | French
CY: | Belgium
JID: | 0404317
ISSN: | 0370-629X
CO: | RMLIAC
Institution: | Service de Santé Publique et d'Epidémiologie, Centre Collaborateur Organisation Mondiale de la Santé pour les Aspects de Santé Publique des Maladies Rhumatismales, Liège.
DT: | English Abstract; Journal Article
Schlagwörter
CT: | ANTHRAQUINONES/pharmacology; ANTHRAQUINONES/therapeutic use; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/pharmacology; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/therapeutic use; CHONDROITIN/pharmacology; CHONDROITIN/*therapeutic use; DISEASE PROGRESSION; GLUCOSAMINE/pharmacology; GLUCOSAMINE/*therapeutic use; HUMANS; HYALURONIC ACID/pharmacology; HYALURONIC ACID/*therapeutic use; OSTEOARTHRITIS/*drug therapy
CTG: | ANTHRACHINONE/Pharmakologie; ANTHRACHINONE/therapeutische Anwendung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/Pharmakologie; ANTIPHLOGISTIKA, NICHTSTEROIDALE/therapeutische Anwendung; CHONDROITIN/Pharmakologie; CHONDROITIN/*therapeutische Anwendung; KRANKHEITSPROGRESSION; GLUCOSAMIN/Pharmakologie; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; HYALURONSÄURE/Pharmakologie; HYALURONSÄURE/*therapeutische Anwendung; OSTEOARTHROSE/*Arzneimitteltherapie
TE: | Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; diacetylrhein/13739-02-1; Glucosamine/3416-24-8; Hyaluronic Acid/9004-61-9; Chondroitin/9007-27-6
CR: | 13739-02-1; 3416-24-8; 9004-61-9; 9007-27-6
AB: | Besides the management of symptoms of osteoarthritis, a lot of interest was raised for molecules aiming at slowing down the structural progression of the disease. This paper summarizes the currently available data allowing to discuss the efficacy and tolerance of these chemical entities.

» Volltext »
» Fenster schließen »